GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies

2025 Proxy Statement Table of Contents Page Letter to Shareholders i Notice of 2025 Annual Meeting of Shareholders ii Record Date ii Voting Matters and Vote Recommendations ii Proxy Statement 1 Proxy Summary 1 Voting and Meeting Information 1 Attendance and Participation 1 Who is Eligible to Vote 2 Advance Voting Methods 2 Voting During the Annual Meeting 3 Questions 3 Our Purpose and Strategic Framework 4 People 4 Products 5 Planet 5 Performance 6 Our Director Nominees and Committee Membership 6 Summary of Director Nominee Skills, Experience and Background 7 Governance Highlights 8 PROPOSAL 1—Election of Twelve Director Nominees to Our Board of Directors 10 PROPOSAL 2—Approval, on an Advisory Basis, of Named Executive Officer Compensation 23 PROPOSAL 3—Ratification of the Appointment of Ernst & Young LLP ("EY") as Our Independent Registered Public Accountant 25 Independent Registered Public Accountant Services and Related Fee Arrangements 25 Report of the Audit Committee 26 Corporate Governance 28 Director Independence 28 Board Leadership Structure 29 Majority Voting for Directors 29 Board Oversight of Risk 29 Board Oversight of ESG and Sustainability Matters 30 Code of Ethics, Code of Conduct and Corporate Governance Guidelines 31 Related Person Transactions 31 Communication with the Board 32 Board and Committees 32 Board Refreshment 37 Board Tenure 37 2024 Non-Employee Director Compensation 38 Non-Employee Director Compensation Highlights 38 Non-Employee Director Retainer and Meeting Fees 38 2024 Non-Employee Director Compensation Table 39 Fully Vested Deferred Shares 40 Ownership of Avient Shares 41 Beneficial Ownership of Our Common Shares 41 Stock Ownership Guidelines for Non-Employee Directors 42 Compensation Discussion and Analysis 43 Executive Summary 43 Executive Compensation Philosophy and Objectives 45 What We Pay and Why: Elements of Compensation 47 Other Aspects of Our Compensation Programs 54 Executive Compensation 59 2024 Summary Compensation Table 59 2024 Grants of Plan-Based Awards 62 Outstanding Equity Awards at 2024 Fiscal Year-End 64 2024 Option Exercises and Stock Vested 65 2024 Non Qualified Deferred Compensation 65 Potential Payments Upon Termination or Change of Control 66 CEO Pay Ratio Disclosure 71 Pay Versus Performance Disclosure 72 Compensation Committee Interlocks and Insider Participation 76 Risk Assessment of the Compensation Programs 76 Compensation Committee Report 76 Miscellaneous Provisions 77 Appendix A 80 In this proxy statement, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. CORPORATE GOVERNANCE PROXY STATEMENT 2025 | Annual Meeting of Shareholders 32 Audit Committee—Primary Responsibilities and Requirements   Assist the Board in fulfilling its oversight responsibilities to shareholders relating to: (1) the integrity of the Company’s financial statements; (2) the Company’s compliance with legal and regulatory requirements with respect to matters that may have a material impact on the financial statements; (3) the independent auditor’s qualifications and independence; and (4) the performance of the Company’s internal audit function and independent auditors. Base Salary Annual Incentive Long-Term Incentive To attract and retain talent Drives the achievement of key business results on an annual basis Directly ties the interests of NEOs to our shareholders Fixed base of cash compensation Performance-based and not guaranteed Helps retain key talent and a majority is performance-based and not guaranteed Weighting 15%—CEO 28%—CFO 32%—Other NEOs Weighting 18%—CEO 21%—CFO 22%—Other NEOs Weighting 67%—CEO 51%—CFO 46%—Other NEOs While the Compensation Committee typically considers comparative compensation information to gain a general understanding of current compensation practices in the market, it does not benchmark or ultimately target a specific percentile or data point in assessing competitiveness for base pay or our incentive programs.

GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies

GLS™ TPEs with Antimicrobial Technologies